Skip to main content

Technology transfer and scale down model development strategy for biotherapeutics produced in mammalian cells

Background

The goal of manufacturing process development for drug substance and drug product is to establish a commercial process capable of consistently producing drug substance/drug product of the intended quality. Based on regulatory requirements, the manufacturing process has to be characterized prior to process validation. Since performing the characterization study at the manufacturing scale is not practically feasible, development of a scale down model that represents the performance of the commercial process is essential to achieve reliable process characterization. The developed scale down model could also be applied for cell line selection, process and medium development, raw material evaluation, limit of cell age studies, process parameter excursions, etc. Process development and commercial production should not be on the critical path to market despite the compressed time-to-market expectations. That is why Technology Transfer (TT) is a vulnerable time for companies. According to World Health Organization, Transfer of technology is defined as "a logical procedure that controls the transfer of any process together with its documentation and professional expertise between development and manufacture or between manufacture sites". In the pharmaceutical industry, Technology Transfer refers to the processes that are needed for successful progress from drug discovery to product development to clinical trials to full-scale commercialization or it is the process by which a developer of technology makes its technology available to commercial partner that will exploit the technology. This article describes the strategies and activities required to develop a scale down model. It also sketches a Technology Transfer approach for bioprocesses by focusing on the upstream part of a cell culture based process.

Results

Scale down model development strategy

"Small-scale models can be developed and used to support process development studies. The development of a model should account for scale effects and be representative of the proposed commercial process. A scientifically justified model can enable a prediction of quality, and can be used to support the extrapolation of operating conditions across multiple scales and equipment [2]. The key elements for designing a scale down model are inputs (raw materials and components, cell source, environmental conditions) and outputs (performance and product quality metrics, sample handling/storage, analytical methods). A scale down model can be equivalent for some outputs but not for all and still be a representative model. It should reproduce at small scale the effect/impact seen at large scale. The acceptability of an observed offset has to be statistically evaluated and scientifically understood.

Technology Transfer strategy

"The goal of Technology Transfer activities is to transfer product and process knowledge from development to market, and within or between manufacturing sites to support product commercialization. This knowledge forms the basis for the manufacturing process,control strategy, process validation approach and ongoing continual improvement [1]. A dedicated Technology Transfer team has to be set up to facilitate and execute the process including experts in different fields (production, QA, QC, RA, MSAT, etc.). The whole Technology Transfer has to be coordinated by the technology transfer/project leader. Organization for Technology Transfer should be established and composed of both party members from both sites, roles and scope of responsibilities of each party should be clarified, and adequate communication and feedback of information should be ensured. Figure 1 describes the main steps of the Technology Transfer. Technology Transfer can be considered successful if the Receiving Unit can routinely reproduce the transferred product, process, or method against a predefined set of specifications as agreed with the Sending Unit. The success of a Technology Transfer project will be largely dependent on the skill and performance of individuals assigned to the project from the Sending Unit and the Receiving Unit. The roles and responsibilities of the sending unit and the receiving unit have to be clearly defined. The documentation is a key element of Technology Transfer: it ensures consistent and controlled procedures for Technology Transfer and to run the process. Clear documentation should provide assurance of process and product knowledge (Table 1).

Figure 1
figure1

Technology Transfer (TT) process flow chart.

Table 1 Technology transfer documentation

Conclusions

A scale down models is a tool for developing and characterizing the process and should be designed and demonstrated as appropriate representations of the manufacturing process. The transfer of technology from R&D to the commercial production site is a critical process in the development and launch of a biotherapeutical product. The three primary considerations to be addressed during an effective technology transfer are the project plan, the people involved and the process.

References

  1. 1.

    ICHQ10 guideline: Pharmaceutical Quality System.

  2. 2.

    ICHQ11 guideline: Development and manufacture of drug substances (chemical entities and biotechnological/biological entities).

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Nadine Kochanowski.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Cite this article

Kochanowski, N., Malphettes, L. Technology transfer and scale down model development strategy for biotherapeutics produced in mammalian cells. BMC Proc 7, P86 (2013). https://doi.org/10.1186/1753-6561-7-S6-P86

Download citation

Keywords

  • Technology Transfer
  • Commercial Process
  • Receive Unit
  • Commercial Partner
  • Technology Transfer Activity